Business Context and Reporting Period
This Form 8-K Current Report, filed on June 6, 2023, covers events occurring between June 2 and June 6, 2023, for Kiora Pharmaceuticals, Inc. (KPRX). The filing details the pricing, closing, and terms of a firm commitment underwritten public offering of equity securities.
Key Financial Metrics and Capital Structure
- Net Proceeds: Approximately $5.6 million after deducting underwriting discounts, commissions, and estimated offering expenses.
- Securities Issued:
- 2,197,628 shares of Common Stock (including 750,000 from the overallotment).
- 3,908 shares of Series F Convertible Preferred Stock.
- 5,750,000 Class C Warrants (5-year term).
- 5,750,000 Class D Warrants (1-year term).
- Offering Price: $1.10 per Common Share and per Warrant; $999.90 per Preferred Share (plus associated warrants).
- Outstanding Shares: Following the offering and conversion of 2,331 Preferred Shares, the Company had 6,340,777 shares of common stock outstanding as of June 6, 2023.
Material Changes
The primary material change is the significant increase in capitalization and share count resulting from the public offering. The Company fully exercised the 45-day overallotment option on June 5, 2023, increasing the total issuance of common shares and warrants by 750,000 units each. Additionally, the Company filed a Certificate of Designation for Series F Convertible Preferred Stock, establishing its conversion rights and seniority relative to other capital classes.
Outlook, Risks, and Unusual Items
- Lock-Up Agreements: The Company and its executive officers and directors are subject to a 90-day lock-up period prohibiting the sale or transfer of securities without underwriter approval.
- Warrant Terms: Warrants include a one-time reset feature where the exercise price may be adjusted to 90% of the five-day volume-weighted average price 60 days after issuance. Beneficial ownership limitations cap exercise at 4.99% (or 9.99% with notice).
- Preferred Stock Rights: Series F Preferred Stock has limited voting rights but requires holder consent for specific corporate actions affecting their rights. It ranks on parity with common stock on an as-converted basis.
- Financial Statements: This filing does not contain audited financial statements, revenue, profit, or cash flow data for the reporting period.
Investor Verification Checklist
- Verify the final net proceeds of $5.6 million against the total gross proceeds and actual offering expenses in the final prospectus.
- Confirm the dilution impact of the 5,750,000 Class C and Class D warrants, noting the potential for exercise price resets.
- Review the conversion mechanics of the Series F Preferred Stock and the 4.99% beneficial ownership limitation.
- Monitor the 90-day lock-up expiration date for potential selling pressure from insiders.
- Check subsequent filings for the actual use of proceeds and any changes to the outstanding share count.